Avastin is an antineoplastic agent, and relates to monoclonal antibodies. Use of the drug contributes to the suppression of metastatic disease progression and reduce microvascular permeability in different types of tumors (breast, prostate, pancreatic, colon).

Release form and composition

Avastin is produced in the form of a concentrate for solution for infusion may have a light brown color or be colorless. The active ingredient in the drug is bevacizumab.

This drug is available in packages with a concentration bevazumaba in vials of 100 mg / 4 ml and 400 mg / 16 ml.


According to the instructions Avastin is indicated for:

  • Metastatic or locally recurrent breast cancer;
  • The spread of inoperable metastatic or recurrent non-squamous non-small cell lung cancer;
  • Distribution and / or metastatic renal cell carcinoma;
  • Metastatic colorectal cancer;
  • Relapsed glioblastoma.

Avastin in ophthalmology due to its effectiveness in the treatment of wet age-related macular degeneration, macular edema, tumor okolomakulyarnoy region, diabetic retinopathy and some other eye diseases, which are related to the abnormal growth of blood vessels. Results of administration Avastin injections into the vitreous prove the efficacy of this procedure and its good tolerance by patients with proliferative diabetic retinopathy. The effect of Avastin in ophthalmology is to stabilize the subretinal neovascular membrane. Side effects from administration of the drug into the vitreous get.


According to the instructions, Avastin should not be used to treat patients with hypersensitivity to the drug, as well as pregnant and lactating women. Avastin is contraindicated in children and individuals with kidney and liver failure, because the effectiveness and safety of the drug for such patients has not been established. All of the above are relevant contraindications and the application of this drug in ophthalmology.

Dosage and Administration

The introduction of the drug intravenously strictly prohibited, allowed only Avastin administered intravenously. Stud required amount of concentrate to the desired volume occurs via 0, 9% sodium chloride solution, thus necessarily includes all rules of sterility. The mixed composition should contain bevacizumab within 1, 4-16, 5 mg / ml. The initial dose of Avastin administered after chemotherapy as an intravenous infusion over 90 minutes, the application of subsequent doses may both after and before chemotherapy. If the patient had a good first infusion, while the second injection is reduced to 60 minutes, while maintaining positive reactions subsequent infusions Avastin held for 30 minutes. In case of adverse events Avastin should be completely or temporarily stop.

Standard dosing

In metastatic colorectal cancer:

  • As a first-line drug 5 mg per 1 kg of body weight one every 2 weeks, or 7.5 mg per 1 kg of body weight 1 to 3 times a week intravenously, slowly.
  • As a preparation of the second line from 5 to 10 mg per kilogram body weight once every two weeks, intravenously, slowly.

In locally recurrent or metastatic breast cancer to 10 mg per 1 kg body weight once every two weeks intravenously, slowly.

With widespread inoperable, recurrent or metastatic non-squamous cell lung cancer Avastin administered at a dose of 7. 5 to 15 mg per kilogram body weight every three weeks, depending on whether, in addition to what type of chemotherapy was prescribed.

If the distribution and / or metastatic renal cell cancer drug administered in a dose of 10 mg per kilogram of body weight once every two weeks intravenously, slowly.

When glioblastoma (glioma grade IV) Avastin administered in a dose of 10 mg per kilogram of body weight once every two weeks intravenously, slowly.

In epithelial ovarian cancer, fallopian tube, and with primary peritoneal cancer drug is administered in a dose of 15 mg per kilogram body weight every three weeks intravenously, slowly.

As a first-line treatment with Avastin administered in addition to carboplatin and paclitaxel, with the maximum duration of the course is 6 cycles of chemotherapy followed by Avastin as a single agent continued.

The total duration of treatment with this drug is 15 months. When symptoms of disease progression treated with Avastin should not continue.

When tumor recurrence Avastin administered in combination with carboplatin and gemcitabine (course 6-10 cycles), then the use of the drug takes place as monotherapy.

side effects

Reviews Avastin suggest that the most serious adverse reactions are manifested in the form of perforation of the gastrointestinal tract, bleeding, including hemoptysis or pulmonary hemorrhage and arterial thromboembolism. It is also often possible to meet complaints of high blood pressure, diarrhea, abdominal pain, fatigue or asthenia. The instructions to Avastin, in addition to those mentioned, indicated the following possible symptoms of adverse reactions to the drug administration:

  • Increased blood pressure, arterial thromboembolism, deep vein thrombosis, congestive heart failure, bleeding;
  • Neutropenia, leukopenia, febrile neutropenia, thrombocytopenia, anemia;
  • Constipation, diarrhea, nausea, vomiting, rectal bleeding, anorexia, stomatitis;
  • Ileus, gastrointestinal disorders, abdominal pain, perforation of the gastrointestinal tract;
  • Rhinitis, epistaxis, dyspnea, hypoxia, pulmonary thromboembolism;
  • Dry skin, changing its color, exfoliative dermatitis, hand-foot syndrome;
  • Increased lacrimation, impaired visual function;
  • Arthralgia, myalgia, muscle weakness;
  • Proteinuria, urinary tract infection;
  • Fatigue, fever, increased fatigue, pain of various localization, abscess, dehydration, sepsis.

It is also possible to reduce the hemoglobin level, the appearance of hyperglycemia, leukopenia, hypokalemia, thrombocytopenia.


During therapy with Avastin and for at least six months after it, men and women of childbearing age must use reliable contraception. Although the content of the instruction to Avastin with all necessary information, the purpose, the preparation of the solution and its dosage should be performed only by experienced specialized physician.

Avastin Pharmaceutical characteristics incompatible with dextrose solution.


By analogues of Avastin, the mechanism of close exposure related to one farm. subgroup include: Vectibix, Herceptin, Campath, MabThera, Erbitux, Arzerra, Removab, Pereta, Herceptin lyophilisate, Rituximab, Atsellbiya, MabThera.

Analogues of the drug for active substances not.

Terms and conditions of storage

According to the instructions of Avastin should be stored in a dark place, at 2-8 ° C. The final solution is considered suitable for use during the day.